CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,823 shares of the company’s stock after selling 2,146 shares during the period. Teacher Retirement System of Texas’ holdings in CRISPR Therapeutics were worth $743,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in CRISPR Therapeutics by 7.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock worth $215,000 after acquiring an additional 372 shares during the last quarter. Horizon Kinetics Asset Management LLC boosted its holdings in shares of CRISPR Therapeutics by 4.3% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company’s stock worth $420,000 after purchasing an additional 443 shares during the last quarter. Capital Group Investment Management PTE. LTD. grew its position in shares of CRISPR Therapeutics by 2.1% in the fourth quarter. Capital Group Investment Management PTE. LTD. now owns 27,698 shares of the company’s stock valued at $1,090,000 after purchasing an additional 582 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of CRISPR Therapeutics by 16.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,346 shares of the company’s stock valued at $171,000 after purchasing an additional 606 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of CRISPR Therapeutics by 3.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,217 shares of the company’s stock valued at $874,000 after purchasing an additional 645 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Buying and Selling

In other news, insider Naimish Patel sold 3,932 shares of the stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider directly owned 6,068 shares in the company, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CRSP has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Chardan Capital reissued a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, June 26th. Barclays cut their price objective on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group decreased their target price on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. Finally, Piper Sandler restated an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $71.75.

CRISPR Therapeutics Trading Down 6.5%

CRSP stock opened at $52.73 on Wednesday. The business’s fifty day moving average price is $43.29 and its 200 day moving average price is $41.48. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $63.68. The company has a market capitalization of $4.55 billion, a PE ratio of -11.67 and a beta of 1.82.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. The firm’s quarterly revenue was up 71.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.43) EPS. Research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.